FDA approves first drug for rare form of rickets

April 23, 2018

(HealthDay)—Ultragenyx Pharmaceutical Inc.'s Crysvita (burosumab-twza) has been approved by the U.S. Food and Drug Administration to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH).

A clinical trial found that 94 percent of adults who took Crysvita once a month achieved normal phosphorus levels, compared with 8 percent of those who took a placebo, according to the FDA. In children, 94 to 100 percent of those treated with Crysvita every two weeks achieved normal phosphorus levels.

The most common negative side effects of Crysvita in adults were back pain, headache, , decreased vitamin D, dizziness, and constipation. The most common in children were headache, injection site reaction, vomiting, decreased vitamin D, and fever, the FDA said.

"XLH differs from other forms of rickets in that vitamin D therapy is not effective," Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, said in an agency news release. "This is the first FDA-approved medication for the treatment of XLH and a real breakthrough for those living with this serious disease."

Explore further: FDA approves pediatric treatment for Chagas disease

More information: More Information

Related Stories

FDA approves pediatric treatment for Chagas disease

August 31, 2017
(HealthDay)—Benznidazole has been approved by the U.S. Food and Drug Administration to treat the tropical parasitic infection Chagas disease, in children aged 2 to 12.

FDA: Akynzeo approved for chemo-related nausea / vomiting

October 11, 2014
(HealthDay)—The combination drug Akynzeo (netupitant and palonosetron) has been approved by the U.S. Food and Drug Administration to treat nausea and vomiting among people undergoing chemotherapy, the agency said Friday ...

First drug approved for rare condition that inflames blood vessels

December 12, 2017
(HealthDay)—Nucala (mepolizumab) has been approved by the U.S. Food and Drug Administration as the first remedy to treat adults with eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease that leads to ...

FDA approves new drugs for irritable bowel syndrome

May 28, 2015
(HealthDay)—Two new drugs for adults with irritable bowel syndrome with diarrhea (IBS-D) were approved by the U.S. Food and Drug Administration on Wednesday.

FDA approves vabomere for complicated UTIs

August 31, 2017
(HealthDay)—The intravenous antibiotic Vabomere (meropenem and vaborbactam) has been approved by the U.S. Food and Drug Administration to treat certain complicated urinary tract infections, including pyelonephritis.

FDA approves once-monthly injection for opioid addiction

December 4, 2017
(HealthDay)—Sublocade, a once-monthly injection of buprenorphine to treat opioid use disorder, has been approved by the U.S. Food and Drug Administration.

Recommended for you

Common use of antipsychotics shown ineffective for delirium in intensive care patients

October 22, 2018
Critically ill patients in intensive care units (ICUs) did not benefit from two antipsychotic drugs used to treat delirium, according to a large clinical trial funded by the National Institute on Aging, part of the National ...

Medicating distress: Risky sedative prescriptions for older adults vary widely

October 18, 2018
Despite years of warnings that older adults shouldn't take sedative drugs that put them at risk of injury and death, a new study reveals how many primary care doctors are still prescribing them, how often, and exactly where.

Medical management of opioid-induced constipation differs from other forms of condition

October 17, 2018
Traditional laxatives are recommended as first-line agents to treat patients with a confirmed diagnosis of opioid-induced constipation (OIC), according to a new guideline from the American Gastroenterological Association ...

Research assesses geographic distribution of new antibiotics following market introduction

October 16, 2018
There is a growing need for new antibiotics to help combat the looming threat of antimicrobial resistance. According to a new study conducted by researchers at the Center for Disease Dynamics, Economics & Policy (CDDEP) with ...

Health insurer policies may discourage use of non-opioid alternatives for lower back pain

October 5, 2018
Public and private health insurance policies in the U.S. are missing important opportunities to encourage the use of physical therapy, psychological counseling and other non-drug alternatives to opioid medication for treating ...

Opioid overdoses, depression linked

October 3, 2018
The link between mental health disorders and substance abuse is well-documented. Nearly one in 12 adults in the U.S is depressed, and opioid-related deaths are skyrocketing. As these numbers continue to climb, some mental ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.